Latest News in the pharma Industry

Research & Development

Acousia Therapeutics receives EUR 2.5 M to develop innovative therapy to treat and prevent sensorineural hearing loss

Acousia Therapeutics receives EUR 2.5 M to develop innovative therapy to treat and prevent sensorineural hearing loss

14 Dec 2016

New shareholder, Axxamof Milan, Italy, will transfer certain therapeutic assets to the R&D programs of Acousia.

Read more 
Lilly and AstraZeneca to develop second potentially disease-modifying treatment for Alzheimer's

Lilly and AstraZeneca to develop second potentially disease-modifying treatment for Alzheimer's

10 Dec 2016

"MEDI1814 has a unique mechanism among antibodies in clinical development and could provide a distinct approach to treating Alzheimer's disease."

Read more 
Albumedix and NYU School of Medicine to investigate targeting novel cellular pathways in oncology

Albumedix and NYU School of Medicine to investigate targeting novel cellular pathways in oncology

6 Dec 2016

Collaboration will explore the potential of novel applications of Albumedix’s albumin-based drug delivery platform, Veltis.

Read more 
Saneca to drive R&D initiative following €1.5 million funding

Saneca to drive R&D initiative following €1.5 million funding

5 Dec 2016

The CDMO’s initiatives include laboratory research for the preparation of APIs, with a particular focus on chiral molecules and emphasis on the principles of sustainable development and ‘green chemistry’.

Read more 
Interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product

Interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product

5 Dec 2016

If approved, the product could provide blood cancer patients with access to potentially life-saving medicine.

Read more 
Novel nanoscale vehicles for drug delivery

Novel nanoscale vehicles for drug delivery

5 Dec 2016

UCL pioneers the engineering of novel nanoscale drug delivery vehicles, which can be tuned to release a range of cargos.

Read more 
FDA approves Jardiance tablets to reduce the risk of cardiovascular death in adults with T2D

FDA approves Jardiance tablets to reduce the risk of cardiovascular death in adults with T2D

5 Dec 2016

The only oral T2D medicine to provide a life-saving cardiovascular benefit.

Read more 
Novartis SEG101 significantly reduces frequency of sickle cell pain crises in Phase II study

Novartis SEG101 significantly reduces frequency of sickle cell pain crises in Phase II study

4 Dec 2016

Represents a potentially novel disease-modifying therapeutic option.

Read more 
CSL commits to new Phase I clinical trials in Australia

CSL commits to new Phase I clinical trials in Australia

3 Dec 2016

Read more 
Type 2 diabetes drugs may be a valuable resource in the treatment of Alzheimer’s disease

Type 2 diabetes drugs may be a valuable resource in the treatment of Alzheimer’s disease

1 Dec 2016

T2DM therapies are capable of modifying the activity of insulin in the brain.

Read more 
Optibrium and MolPort collaborate to improve speed and cost-efficiency of drug discovery

Optibrium and MolPort collaborate to improve speed and cost-efficiency of drug discovery

30 Nov 2016

Partnership combines MolPort’s 6.3 Million HTS Compounds with StarDrop’s data analysis and compound design capabilities.

Read more 
FDA accepts BLA for avelumab for the treatment of metastatic MCC for Priority Review

FDA accepts BLA for avelumab for the treatment of metastatic MCC for Priority Review

29 Nov 2016

If approved by the FDA, avelumab could be the first treatment indicated for patients with metastatic Merkel cell carcinoma.

Read more